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Abstract
Background: Many chemotherapeutic agents promote tumor cell death by activating the intrinsic pathway of
apoptosis. Intrinsic apoptosis involves permeabilization of the mitochondrial outer membrane and the release of
cytochrome c, a process that is controlled by proteins of the BCL2 gene family. Chemoresistance is often associated
with abnormalities in concentrations of BCL2 family proteins. Although stoichiometirc interactions between anti-
apoptotic and BH3-only BCL2 family proteins have been well documented as affecting cell death, the association
between changes in BAX concentration and intrinsic apoptosis are poorly understood.
Methods: Exogenous GFP-murine Bax fusion constructs were transfected into BAX-deficient HCT116 cells. To titrate
the expression of the fusion protein, GFP-BAX was cloned into a tetracycline sensitive expression cassette and
cotransfected with a plasmid expressing the rtTA transcription factor into HCT116
BAX-/- cells. Linear expression of
the fusion gene was induced with doxycycline and monitored by quantitative PCR and immunoblotting. Cell death
was assayed by DAPI staining cells after exposure to indomethacin, and scoring nuclei for condensed chromatin
and fragmented nuclei.
Results: HCT116
BAX-/- cells were resistant to indomethacin, but susceptibility could be recovered in cells expressing
a GFP-BAX fusion protein. Titration of GFP-BAX expression revealed that the concentration of BAX required to
induce a saturating apoptosis response from baseline, was rapidly achieved. Increased levels of GFP-BAX were
unable to stimulate higher levels of cell death. Examination of GFP-BAX distribution before and after indomethacin
treatment indicated that BAX protein did not form aggregates when present at sub-lethal concentrations.
Conclusion: Within the limitations of this experimental system, BAX-dependent apoptosis in HCT116 cells exhibits
an all-or-none response depending on the level of BAX protein present. The lack of BAX aggregation at sub-
saturation levels suggests that the translocation step of BAX activation may be impaired.
Background
Intrinsic apoptosis is the principal autonomous
self-destruct pathway executed by cell somas. Multiple
chemotherapeutic agents and radiation are effective by
activating this pathway in dividing cells. The critical reg-
ulatory step of this pathway involves mitochondrial dys-
function, which occurs through a process controlled by
related proteins forming the BCL2 gene family. Mem-
bers of this family share common BCL-2 Homology
(BH) domains, which affect their interactions with lipid
bilayers and each other [1]. The exact nature of the acti-
vation steps are not well known, but pro-apoptotic
molecules, such as BAX and BAK, exist in conforma-
tionally inactive states in living cells. BAX, for example,
is a globular protein in the cytosol. Upon the activation
of apoptosis, BAX unfolds to expose critical domains
that enable it to translocate and insert to the mitochon-
drial outer membrane (MOM), and then form multi-
meric aggregates with itself [2-4]. These aggregates
facilitate the release of cytochrome c, either by forming
pores in the MOM, or by a direct destabilization of the
lipid bilayer. BAX insertion and aggregation is the point
of no return in the apoptotic pathway [5]. Once
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vated, and dying cells are subjected to proteolytic break-
down. In addition to the release of cytochrome c,
BAX-dependent mitochondrial dysfunction also disrupts
electron transport thereby destabilizing the proton gra-
dient across the inner membrane, causing a loss of ATP
production and the formation of superoxide anions and
other free radicals.
Antagonizing the function of pro-apoptotic BAK and
BAX, are anti-apoptotic family members such as BCL2
and BCLXL. These proteins generally exist in or at the
surface of the MOM, and may interact directly with
BAK and BAX to prevent an accidental insertion event
at the membrane surface. The balance between pro- and
anti-apoptotic molecules is critical, even though some
cells reportedly have several fold more anti-apoptotic
molecules in abundance than the pro-apoptotic counter-
parts. At the onset of apoptosis, cells typically activate a
several different species of BH3-only proteins, which
reportedly preferentially bind to and inactivate the
excess numbers of anti-apopt o t i cB C L 2f a m i l yp r o t e i n s .
The threshold of BH3-only proteins is apparently set by
the concentration of proteins like BCL2, and recent stu-
dies indicate that all anti-apoptotic molecules must be
sequestered before cell death can occur [6,7]. This pur-
ported stoichiometric balance between proteins like
B C L 2a n dB H 3 - o n l yp r o t e i n si st h ef o u n d a t i o no ft h e
modified rheostat model of BCL2 family function origin-
ally hypothesized by the late Dr. Stanley Korsmeyer
[8,9]. In the revised model, the concentration of BAX is
not a critical component of the ability of a cell to ade-
quately neutralize anti-apoptotic BCL2 proteins.
Alterations of the concentrations of BCL2 family pro-
teins can have dramatic effects on cell death. Cells that
exhibit resistance to chemotherapy, for example, often
show elevated expression of anti-apoptotic proteins [10].
This has led to the development of a new series of
potential chemotherapeutic agents that target the pro-
cess of apoptosis directly, and include small molecules
that bind to the hydrophobic groove of anti-apoptotic
proteins and antagonize their function [11]. Presumably,
these antagonists augment the effects of naturally
expressed BH3-only proteins, which normally could not
neutralize excess molecules of BCL2 or BCLXL.
Even though not directly relevant to the balance
between anti-apoptotic and BH3-only BCL2 family
proteins, conditions that result in lower than normal
BAX expression can also affect cell death. BAX gene
mutations that reduce transcription levels, or produce
dysfunctional protein, have been correlated with
increased resistance of cells in lymphocytic leukemia
and colorectal carcinoma, respectively [12-14]. In addi-
tion, various neuronal cell-types, which rely solely on
BAX for pro-apoptotic activity, become highly resistant
to lesions of the nervous system when their BAX levels
are reduced [15-18].
The development of successful strategies to influence
the balance of BCL2 family proteins in target cells
requires a complete understanding of the activation
events and interactions between members of this gene
family. Our early studies on the role of BAX in neuronal
death suggested that apoptosis was critically dependent
on the level of this pro-apoptotic protein to execute the
cell death pathway, irrespective of the concentration of
anti-apoptotic molecules present [18]. In this report, we
extend these observations to HCT116 colorectal carci-
noma cells, which, like neurons, are completely depen-
dent on BAX for apoptosis. HCT116 cells are
susceptible to non-steroidal anti-inflammatory drugs,
while HCT116
BAX -/- cells are completely resistant. Sus-
ceptibility in BAX-deficient cells can be rescued if they
express an exogenous BAX gene, but only after a critical
level of expression has been achieved. Furthermore,
experiments using a GFP-BAX fusion protein, indicate
that normal aggregation of BAX is impaired at non-
lethal levels, suggesting that the level of BAX is critical
for the successful activation of this proapoptotic protein,
a n dn o tr e l a t e dt oo v e r c o m i n gad e f i n e dn u m b e ro f
anti-apoptotic proteins.
Methods
Clones and plasmids
To generate the GFP-BAX fusion protein construct,
murine Bax was cloned into pEGFP-C3 (Clontech, Palo
Alto, CA) by first amplifying Bax cDNA using the fol-
lowing primers: 5’ACC CGC CGA GAG GCA GCG
(forward) and 5’CAC AGT CCC AGG CAG TGG G
(reverse). Nested PCR was used to engineer a HindIII
and EcoRI site onto the Bax cDNA for in-frame ligation
to the C-terminus of GFP.
To generate constructs in the pTRE-Tight vector
(Clontech), GFP-BAX was amplified from the pEGFP-
C3 plasmid using 5’GCA TGC GAT AGG TAC CAT
GGT GAG CAA GGG CGA GG (forward, includes
KpnIs i t e )a n d5 ’GTC GCG TCC TAA GCT TTC AGC
CCA TCT TCT TCC (reverse, includes HindIII site).
The resulting PCR fragment was first blunt-ended and
then cut with KpnI. This fragment was ligated into the
pTRE-Tight vector cut with KpnIa n dNotI, which had
been back-filled with Klenow enzyme. GFP alone was
cloned into pTRE-Tight by utilizing the above primers,
but cutting the insert with KpnIa n dHindIII to excise
GFP alone.
An S16 ribosomal protein cDNA was amplified using
primers: 5’CAC TGC AAA CGG GGA AAT GG (for-
ward) and 5’TGA GAT GGA CTG TCG GAT GG
(reverse). All cDNAs were blunt-end cloned into the
Sma I site of pBK-CMV (Stratagene, La Jolla, CA).
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Total RNA from transfected HCT116 cells was isolated
using Tri-reagent (Molecular Research Center, Cincin-
nati, OH) and treated extensively with DNase I to elimi-
nate contaminating genomic and transfected DNA. First
strand cDNA was synthesized and quantitative PCR was
performed using the Applied Biosystems (ABI, Foster
City, CA) 7300 real time PCR system and ABI SYBR
Green PCR Master Mix as described previously [19].
Control reactions, using samples made without reverse
transcriptase were also run to verify amplification was
from cDNA templates. Standard curves were generated
for each product using cloned cDNAs for GFP-Bax and
S16 ribosomal protein to quantify the abundance of
cDNA in each unknown. The qPCR cycling parameters
were: 1 cycle of 95°C for 10 min, 40 cycles of 95°C for
15 s and 60°C for 1 min. Data collection was taken at
the 60°C annealing/extension phase. In order to ensure
t h ep r e s e n c eo fas i n g l ep r o d u c t ,ad i s s o c i a t i o nc u r v e
was performed after each run and products visualized
on ethidium bromide-stained agarose gels. Data were
collected from threshold values using the automatic
function of the 7300 System Sequence Detection Soft-
ware program. The primers used to quantify Bax cDNA
were: 5’TTC ATC CAG GAT CGA GCA GG (forward)
and 5’ CAT CAG CAA ACA TGT CAG C (reverse).
The primers used to quantify S16 ribosomal protein
cDNA, were the same primers that were used to clone
S16 above.
Cell culture
All cells were maintained in a humidified incubator at
37°C with 5% CO2. Medium was changed every 2-3
days. Human colorectal cancer cells lacking a functional
BAX gene, HCT116
BAX-/- [20], were a gift from Dr. Bert
Vogelstein. These cells were cultured in McCoy’s5 A
Medium (Modified) with 25 mM Hepes and L-
glutamine (Cambrex, Walkersville, MD), and supple-
mented with 10% Fetal Bovine Serum (FBS) (certified
tetracycline free - Atlanta Biologicals, Atlanta, GA) and
1% penicillin/streptomycin. HCT116 cells were treated
with 500 μMi n d o m e t h a c i n( S i g m a ,S t .L o u i s ,M O ) ,2 4
hrs after transfection (see below) to induce cell death
for threshold experiments. Cells attached to the plate
and those floating in the medium were harvested 48 hrs
after treatment, fixed in 3.7% formaldehyde and 0.5%
Igepal CA-630, and DAPI stained. Cells with condensed
chromatin and fragmented nuclei were scored as apop-
totic as described previously [20].
Transfections
HCT116 cells were plated at a density of 1 × 10
6 cells/
well into 6-well plates. All cells were transfected 24 hrs
after initial plating. Transfections were performed using
the Tfx-50 transfection reagent (Promega) with a 2:1
(transfection reagent: DNA) ratio. Plasmid DNAs used
for transfection of HCT116 cells were 1 μgo fe i t h e r
pTRE-GFP or pTRE-GFP-BAX co-transfected with 1 μg
of pTet-ON (Clontech). The transfection media was
replaced after 5 hrs with complete media containing
increasing concentrations of doxycycline (DOX -
Sigma), from 0 ng/ml to 100 ng/ml. Transfection effi-
ciency for HCT116 cells was evaluated by counting the
number of GFP positive cells and calculating the per-
centage based on the total number of cells. For cell
death controls, HCT116 cells were transfected with 2 μg
of pGL3-Control, pTRE-GFP-BAX, or pTet-ON.
Immunoblotting
Immunoblots were performed as described previously
[21] with modifications. Lysates from HCT116
BAX-/-
cells were used for immunoblots (60 μg/lane). Protein
concentration was quantified using the Pierce BCA Pro-
t e i nA s s a y( T h e r m oS c i e n t i f i c ,R o c k f o r d ,I L ) .R a b b i t
polyclonal antibodies against BAX (B3428) or ACTIN
(A2066), were purchased from Sigma and used at
1:2,000 and 1:100 dilutions, respectively. A goat polyclo-
nal antibody against GFP (T-19) (sc-5384) was pur-
chased from Santa Cruz Biotechnology (Santa Cruz,
CA) and used at a 1:100 dilution. Goat anti-rabbit sec-
ondary antibodies conjugated to alkaline phosphatase
were used to visualize antibodies against BAX and
ACTIN, while a donkey anti-goat secondary antibody
conjugated to horse radish peroxidase was used to
visualize the antibody against GFP. Immunoblots were
developed with the ECL Western Blotting Detection
Reagent from Amersham (Piscataway, New Jersey),
scanned on a Storm 860 scanner (Amersham), and
band density quantified using ImageQuant v5.2
(Amersham).
Fluorescent microscopy
Cells were plated, grown, and transfected in tissue cul-
ture well slides (Fisher Scientific, Chicago, IL). At the
end of each experiment, the cells were fixed as described
above, DAPI-stained, and coverslipped. Fluorescent
photomicrographs were acquired using a Zeiss Axioplan
2 Imaging microscope with digital camera (Zeiss,
Thornwood, NY). Images were pseudo-colored using
Zeiss Axiovision Image Analysis software (v4.6). For gra-
phic presentation, these images were imported into
Adobe Photoshop, but were not enhanced further.
Statistical analyses
For data presented as mean ± SEM, assessment for sig-
nificant differences between groups was performed by
Student’s t-test. A level of P ≤ 0.05 was used to desig-
nate significance.
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Susceptibility to indomethacin can be restored in
HCT116
BAX-/- cells by transfection with an exogenous
GFP-Bax fusion construct
HCT116 cells are susceptible to the non-steroidal anti-
inflammatory drug indomethacin, which activates the
intrinsic apoptotic program. Unlike other cell types,
which utilize both BAX and BAK, this program is solely
reliant on BAX function [20], and cells lacking a func-
tional BAX gene are normally resistant (Figure 1A). To
determine if susceptibility of HCT116
BAX-/- cells could
be restored by the expression of an exogenous BAX pro-
tein, we transfected them with a plasmid expressing a
GFP-BAX fusion protein under control of the CMV
immediate early gene promoter. These cells were treated
with indomethacin, 24 hours after transfection, and cell
death was assayed after 48 hours. Cells expressing a
control plasmid containing only GFP exhibited a modest
increase in apoptosis after exposure to indomethacin,
suggesting some toxicity associated with the transfection
protocol. Cells expressing the GFP-BAX fusion protein,
however, exhibited a substantial and significant increase
in cell death, but only after treatment with indometha-
cin (P = 0.0001, compared to GFP-transfected cells, Fig-
ure 1B). Examination of GFP expressing cells also
indicated that these cells accounted for the majority of
dying cells in this paradigm (data not shown).
The cell death response in HCT116
BAX-/- cells is rapidly
saturated with increasing levels of exogenous GFP-Bax
expression
In order to test the association between the level of
BAX expression and the ability to activate the apoptotic
program, HCT116
BAX -/- cells were co-transfected with a
pTRE-plasmid, carrying a tetracycline responsive promo-
ter expressing either GFP-BAX or GFP, and pTetON,
which codes for the reverse tetracycline transcription
activator, rtTA. Transgene expression was induced for
24 hrs by the presence of doxycycline (DOX) in the
media. Both mRNA and protein levels showed a linear
increase in abundance between 0-10 ng/ml DOX
(Figure 2, R
2 = 0.991 for mRNA levels and R
2 = 0.975
for protein levels), after which levels increased non-
linearly. A low level of GFP-BAX was detected in cells
treated with 0 ng/ml DOX, suggesting basal transcrip-
tion from the pTRE-GFP-BAX vector when co-trans-
fected with pTetON. Cells transfected with pTetON
alone, or pTRE-GFP-BAX alone, acted as negative con-
trols for transgene expression. Cells transfected with
pTRE-GFP-BAX exhibited only 17.6% of the level of
fusion protein detected in doubly transfected cells in 0
ng/ml DOX. After 24 hrs in varying concentrations of
DOX, co-transfected cells were treated with indometha-
cin to induce apoptosis and cell death was assayed after
48 hrs. Transfection of control vectors alone was
Figure 1 Transient transfection of GFP-BAX fusion protein into HCT116
BAX-/- cells rescues cell death after Indomethacin treatment.( A )
HCT116
BAX-/- cells are resistant to indomethacin. Line graph showing percentage of apoptotic cells in the medium after exposure of 500 μM
indomethacin for wild type (WT) and BAX-deficient HCT116 cells over time. (B) Rescue of the cell death phenotype by transfection of an
exogenous GFP-Bax gene. HCT116
BAX-/- cells were transfected with either no plasmid, pEGFP-C3 (GFP), or pEGFP-C3-BAX (GFP-BAX), which
expresses a fusion protein of GFP in phase with the murine Bax coding region under the control of the CMV immediate early promoter. Twenty-
four hours after transfection, cells were treated with 500 μM indomethacin (+Indo) or vehicle (-Indo). Transfection efficiency was ~60% in each
condition, based on the proportion of cells positive for GFP expression. Forty-eight hours after indomethacin treatment, cell death was assessed.
Transfection of GFP-BAX into cells that were later treated with indomethacin caused a significant increase in death over GFP transfection and
indomethacin-treated cells (t-test, *P = 0.0001). Values shown are mean ± SD in both graphs of data collected from 3 independent experiments.
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stimulated by 0-0.5 ng/ml DOX was insufficient to
cause cell death above this background level (P =0 . 4 0 )
(Figure 3A). At the DOX concentration of 1 ng/ml, sig-
nificant cell death was observed (P =6 . 1×1 0
-6,G F P -
BAX vs. GFP), which did not increase at higher concen-
trations of DOX (P = 0.47) (Figure 3A). Although the
level of cell death induced was lower than that observed
for HCT116
BAX+/+ c e l l s ,i tc o r r e s p o n d e dt ot h e4 0 %
transfection efficiency observed in our experiments. To
determine if transgene expressing cells were dying, we
verified microscopically that the majority (~80%) of
GFP-BAX positive cells also exhibited condensed or
fragmented apoptotic nuclei (Figure 3B).
GFP-BAX aggregation is impaired at sub-lethal levels of
expression
The activation of BAX during apoptosis is simplistically
divided into four basic steps, including initial activation
(conformational change) of cytosolic monomers, translo-
cation to the MOM and insertion into this membrane,
secondary recruitment of inactivate BAX monomers by
MOM-bound BAX molecules, and aggregation of bound
and recruited BAX molecules into oligomers that enable
the release of cytochrome c. We investigated if BAX
aggregation was altered at non-lethal levels of fusion
protein by monitoring the subcellular localization of
GFP-BAX in HCT116
BAX-/- cells, before and after, indo-
methacin treatment (Figure 4). Others, using similar
GFP-BAX constructs, had demonstrated that BAX loca-
lization changed from a diffuse labeling pattern to more
punctate foci, co-localizing with mitochondrial markers,
as active protein translocates and aggregates to the
MOM [22,23]. In this experimental paradigm, the distri-
bution of GFP-BAX was examined after 18 hours of
indomethacin exposure to ensure that cells in an inter-
mediate stage of apoptosis could be examined. Cells
expressing GFP-BAX at non-lethal levels exhibited
nearly 100% diffuse localization of this fusion protein,
with no evidence of significant redistribution of protein
to a punctate labeling pattern after indomethacin treat-
ment (P = 0.195) (Figure 4A-C). At two levels of lethal
GFP-BAX expression, however, cells exhibited a signifi-
cant increase in punctate labeling after indomethacin
treatment (P = 0.0002, and P =8 . 9×1 0
-8,f o r2n g / m l
and 10 ng/ml DOX treatment, respectively) (Figure
4D-I). Thus, the distribution of GFP-BAX after 18 hours
correlated with resistance or susceptibility of these cells
to indomethacin-induced apoptosis after 48 hours.
Discussion
Previously, we had observed that the ability of some
neurons to execute BAX-dependent cell death was
linked to the level of BAX expression in these cells [18].
Figure 2 Titration of GFP-BAX transgene expression in
HCT116
BAX-/- cells. HCT116
BAX-/- cells were co-transfected with
pTetON and pTRE-GFP-BAX and exposed to increasing
concentrations of DOX in the media. (A) Quantification of transgene
transcripts using quantitative (Real-Time) PCR. Data shown were
normalized to S16 cDNA in each sample and indicated as a
percentaqe of the transcript level at 0 ng/ml DOX (mean ± SEM of
triplicate samples from 3 separate experiments used for
calculations). Levels of transgene mRNA increased linearly with
increasing concentrations of DOX up to 10 ng/ml (R
2 = 0.991). (B)
Immunoblot of transgene expression. GFP-BAX protein expression
increased with increasing concentrations of DOX. Low levels of GFP-
BAX were detected in cells treated with 0 ng/ml DOX, but not in
controls of each plasmid transfected individually (right hand lanes).
ACTIN levels in each lane are shown as a loading control. (C)
Quantification of GFP-BAX protein expression. Transgene protein
levels were quantified, normalized to the amount of ACTIN present
in the same sample, and expressed as the percentage of protein
levels detected in 0 ng/ml DOX (mean ± SEM of data collected
from 5 independent gels). Similar to transcript levels, increasing
concentrations of DOX produced a linear increase in transgene
protein expression (between 0 and 5 ng/ml DOX, R
2 = 0.975).
Semaan and Nickells BMC Cancer 2010, 10:554
http://www.biomedcentral.com/1471-2407/10/554
Page 5 of 9This dependence on the BAX concentration was inde-
pendent of the concentration of the principal antagoniz-
ing anti-apoptotic protein, BCLXL,w h i c hw a sa tl e a s t
10-fold more abundant in these cells [18,24]. A similar
dependence for BAX protein was also observed in BAX-
deficient HCT116 cells.
The original rheostat hypothesis of BCL2 family pro-
tein function [8] predicted that pro- (i.e., BAX) and
anti- (i. e., BCLXL) apoptotic proteins could form dimers
thereby neutralizing each other. In this model, the
expression of BH3-only proteins competed with BCLXL:
BAX dimers and facilitated the release of BAX allowing
to become active. This model has been re-examined [9],
in light of data showing that heterodimers cannot form
under physiologic conditions [25,26]. Instead, the stoi-
chiometric balance between anti-and pro-apoptotic
proteins appears to involve proteins like BCLXL (anti-
apoptotic) and BH3-only proteins (pro-apoptotic) that
are expressed or activated in cells stimulated to undergo
the apoptotic program. Interaction of anti-apoptotic
proteins and BH3-only proteins results in neutralization
of the former. This facet of the apoptotic activation cas-
cade does not necessarily result in BAX activation, how-
ever, and similarly the concentration of BAX likely does
n o ti m p a c tt h es t o i c h i o m e t r ic balance between them.
Activation of BAX appears to require an independent
interaction with a BH3-containing protein [27-29],
which allows it to change conformation in the cyto-
plasm from a globular monomeric protein to one that is
able to translocate and insert into the MOM.
If the dependence for a critical level of BAX protein to
activate apoptosis is not associated with the stoichio-
metric balance between anti-apoptotic and BH3-only
proteins, an alternative effect influenced by BAX protein
levels may be in the process of BAX activation itself.
The impairment of BAX translocation and/or
Figure 3 Indomethacin-induced apoptosis in HCT116
Bax-/- cells becomes rapidly saturated with increasing levels of a GFP-BAX fusion
protein. HCT116
Bax-/- cells were co-transfected with a pTRE-plasmid (carrying either GFP-BAX or GFP) and pTetON, and transgene expression was
induced by increasing concentrations of Doxycycline (DOX) in the media. After 24 hrs, cells were treated with indomethacin and cell death
assayed 48 hrs later. Cells were also transfected with control plasmids alone and exposed to 100 ng/ml DOX. (A) A histogram showing the
percent apoptotic cells 48 hrs after indomethacin treatment at different DOX concentrations (mean ± SEM of 3 separate experiments).
Transfection of control vectors alone (pTRE-GFP-BAX, pTRE-GFP, pTetON, and pGL3-Control), or pTetON combined with pTRE-GFP, was observed
to elicit 8-10% cell death, indicating that the transfection procedure itself was mildly toxic to these cells. GFP-BAX expression stimulated by 0-0.5
ng/ml DOX was insufficient to cause cell death above these background levels (P = 0.40). At the DOX concentration of 1 ng/ml, however,
significant cell death was observed (*P = 6.1 × 10
-6, GFP-BAX vs. GFP). Concentrations of DOX greater than 1 ng/ml did not stimulate apoptosis
above this level (P = 0.47). (B) A representative photomicrograph of cells transfected with GFP-BAX. DAPI-staining (left panel) showed several
cells with normal nuclei and one cell with a fragmented nucleus and condensed chromatin (arrow). GFP imaging of the same field of cells
(center) showed one cell expressing the GFP-BAX transgene. GFP-BAX was distributed in a punctate labeling pattern and was localized to the
single apoptotic cell in the field (merged image). At this time point after indomethacin treatment, approximately 80% of apoptotic cells were
found to be expressing GFP-BAX. Scale bar = 5 μm.
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interpreted in several ways, depending on the rate-limit-
ing step for BAX activation.
First, the interaction of BAX with a binding partner
could be affected by low levels of BAX protein,
especially if the binding partner had a reduced affinity
for BAX in its globular conformation. Candidates for
these binding partners are the BH3-only proteins, which
like BIM, have been shown to have higher affinities for
anti-apoptotic BCL2 family members and can only bind
Figure 4 BAX aggregation is disabled at sub-threshold levels of expression. All photomicrographs of GFP-BAX staining (with DAPI
counterstain) were taken 18 hours after vehicle treatment (A, D, G) or indomethacin treatment (B, E, H). Exposure times were adjusted
automatically to maximize detection of GFP-BAX localization. As a consequence, the level of fluorescent intensity of the fusion protein in each
condition appears similar, even though protein levels linearly increase with increasing doxycycline (DOX) concentration (see Figure 2). (A-C)
HCT116 cells expressing a sub-lethal level of GFP-BAX induced by 0.5 ng/ml DOX. (A) GFP-BAX localization was diffuse in cells not exposed to
indomethacin. This pattern of distribution remained unchanged in cells after indomethacin treatment (B). (C) Quantitative analysis of GFP-BAX
distribution between conditions. There was no significant increase in punctate labeling of GFP-BAX after indomethacin treatment (*P = 0.195).
(D-F) HCT116 cells expressing a supra-lethal level of GFP-BAX induced by 2 ng/ml DOX. Addition of indomethacin caused the redistribution of
GFP-BAX from a diffuse pattern (D) to a punctate pattern (E). Quantitative analysis (F) of the distribution of GFP-BAX showed a significant shift in
the proportion of cells with punctate labeling (**P = 0.0002). (G-I) HCT116 cells expressing a supra-lethal level of GFP-BAX induced by 10 ng/ml
DOX. Similar to cells in (D-F), GFP-BAX showed a significant increase in punctate labeling after indomethacin treatment (***P = 8.9 × 10
-8). Data
for GFP-BAX distribution was collected from a minimum of 100 GFP positive cells per condition and the distribution was scored by 2 masked
observers. Scale bar = 5 μm.
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interacting and unfolding cytosolic BAX would be ther-
modynamically unfavorable in the presence of low BAX
concentrations.
Second, the translocation and aggregation of BAX at
the MOM may also be concentration dependent. Cur-
rent models suggest that very few cytosolic BAX mole-
cules actually need to be independently activated (by
BH3-only proteins) and translocated, since once they
are present in the MOM they act as a sink to capture
other BAX molecules, even if the latter are missing their
C-terminal mitochondrial targeting domains [4,31].
Under these conditions, aggregation by cooperative
binding may rely on passive diffusion of cytosolic BAX,
which are only captured at the MOM when they ran-
domly collide with MOM-bound BAX proteins. The
lethal concentration of BAX would be defined as the
point when random collisions occurred rapidly enough
to allow for the timely activation of the apoptotic pro-
gram; a process that would clearly be affected by the
concentration of cytosolic BAX proteins. Eventually,
however, one would predict that enough BAX would
accumulate in these cells that the apoptotic pathway
could be activated. Our titration experiments support
this hypothesis since fewer cells show punctate labeling
at 18 hrs when treated with 2 ng/mL DOX (Figure 4F),
even though they clearly exhibited a saturated apoptotic
response at 48 hrs (Figure 3A). Similarly, Bax
+/- mice,
which show neuronal resistance to optic nerve damage
at 2 weeks after injury, eventually exhibit dying cells
after several months. In contrast, Bax
-/- cells remain
resistant indefinitely [18].
The activating steps of BAX represent a complex pro-
cess that is not completely understood. Critically, we
demonstrated that a very small alteration in the level of
BAX was the difference between prolonged cell survival
and rapid onset cell death. Thus, the apoptotic switch
mechanism involving BCL2 family proteins appears to
have two different concentration-dependent compo-
nents. One, in which a sufficient number of antagoniz-
ing BH3-only molecules are required to adequately
sequester anti-apoptotic proteins [6,7], and a second,
dependent on the level of BAX expression to success-
fully activate the apoptotic program.
Conclusion
By titrating BAX expression in BAX-deficient HCT116
cells, we demonstrate that the BAX-dependent apoptotic
program becomes rapidly saturated with increasing BAX
protein. The level of BAX expression appears to affect
its ability to form aggregates, which is impaired at sub-
lethal concentrations of protein. This marks a second
level of control for function of the BCL2 gene family
switch that is dependent on the overall cellular concen-
tration of interacting family members.
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